Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
03/23/2023 - 08:00 AM
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.
The following abstracts will be presented as encore poster presentations at the ISN World Congress of Nephrology 2023:
Atrasentan Abstract WCN23-1085 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy – The ALIGN Study Date/Time: Friday, March 31, 2023 at 17:00 – 18:00 ICT Author: Hiddo J. L Heerspink, University Medical Center Groningen, Groningen, Netherlands Abstract WCN23-1126 Atrasentan for the Treatment of IgA Nephropathy: Interim Results of the AFFINITY Study Date/Time: Friday, March 31, 2023 at 17:00 – 18:00 ICT Author: Sung Gyun Kim, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea Abstract WCN23-1117 Atrasentan in Patients with Proteinuric Glomerular Diseases – The AFFINITY Study Date/Time: Saturday, April 1, 2023 at 17:00 – 18:00 ICT Author: Sung Gyun Kim, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea BION-1301 Abstract WCN23-1175 Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy Date/Time: Friday, March 31, 2023 at 17:00 – 18:00 ICT Author: Jonathan Barratt, University of Leicester, Leicester, Leicestershire, United Kingdom Abstract WCN23-1107 A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy Date/Time: Friday, March 31, 2023 at 17:00 – 18:00 ICT Author: Sung Gyun Kim, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea
The following abstract on atrasentan was sponsored by the authors and will be presented as a poster presentation at the ISN World Congress of Nephrology 2023:
Abstract WCN23-1030 Effects of Atrasentan on Markers of Liver Function in Patients with Type 2 Diabetes and Chronic Kidney Disease Date/Time: Saturday, April 1, 2023 at 17:00 – 18:00 ICT Author: Hiddo J. L Heerspink, University Medical Center Groningen, Groningen, Netherlands
For more information on these and other abstracts, please visit the ISN World Congress of Nephrology 2023 website.
About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit www.chinooktx.com .
KDNY Rankings
N/A Ranked by Stock Gains
KDNY Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Commercial Services, Miscellaneous Commercial Services, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Berkeley
About KDNY
chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.